S100B and melanoma: Prognostically, levels of ctDNA have been found to significantly correlate with clinically-relevant, serological markers of tumor burden such as S100 calcium-binding protein B (S100B), melanoma inhibitory activity (MIA) and lactate dehydrogenase (LDH) (Sanmamed et al., 2015; Calapre et al., 2017).